Dr. Reddy's Laboratories (RDY) News Today $15.44 -0.23 (-1.47%) As of 01/3/2025 05:39 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Dr. Reddy's Laboratories (NYSE:RDY) Shares Pass Above Two Hundred Day Moving Average - What's Next?Dr. Reddy's Laboratories (NYSE:RDY) Share Price Passes Above 200-Day Moving Average - What's Next?January 4 at 3:58 AM | marketbeat.comDr. Reddy's Laboratories (NYSE:RDY) Shares Gap Up - What's Next?Dr. Reddy's Laboratories (NYSE:RDY) Shares Gap Up - Still a Buy?December 27, 2024 | marketbeat.comDr. Reddy's Laboratories (NYSE:RDY) Shares Gap Up - Here's What HappenedDr. Reddy's Laboratories (NYSE:RDY) Shares Gap Up - Here's WhyDecember 20, 2024 | marketbeat.comDr. Reddy's Laboratories (NYSE:RDY) Trading 4.7% Higher - Should You Buy?Dr. Reddy's Laboratories (NYSE:RDY) Trading Up 4.7% - Time to Buy?December 19, 2024 | marketbeat.comDr. Reddy's Laboratories (NYSE:RDY) Stock Rating Lowered by NomuraNomura cut shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday.December 19, 2024 | marketbeat.comNational Bank of Canada FI Sells 180,921 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)National Bank of Canada FI trimmed its holdings in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 98.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,199 shares of the company's stock after sellDecember 17, 2024 | marketbeat.comWorld Investment Advisors LLC Makes New $3.46 Million Investment in Dr. Reddy's Laboratories Limited (NYSE:RDY)World Investment Advisors LLC bought a new stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 43,539 shares of the company's stock, valued at approximatelDecember 14, 2024 | marketbeat.comDr. Reddy's Laboratories Limited (NYSE:RDY) Shares Sold by Jane Street Group LLCJane Street Group LLC cut its position in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 34.1% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 192,189 shares of the company's stock after selling 99,620 shares during theDecember 13, 2024 | marketbeat.comDr. Reddy's Laboratories (NYSE:RDY) Lowered to Hold Rating by StockNews.comStockNews.com lowered Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research report on Friday.December 6, 2024 | marketbeat.comDr. Reddy’s Boosts Workforce with Equity AllotmentDecember 3, 2024 | markets.businessinsider.comDr. Reddy's Launches Toripalimab For Nasopharyngeal Carcinoma In IndiaNovember 28, 2024 | markets.businessinsider.comWhat is Zacks Research's Forecast for RDY FY2025 Earnings?Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) - Stock analysts at Zacks Research upped their FY2025 earnings per share (EPS) estimates for Dr. Reddy's Laboratories in a research report issued on Tuesday, November 26th. Zacks Research analyst R. Department now expects that the companyNovember 28, 2024 | marketbeat.comDr. Reddy’s Fined in Germany for Registration LapseNovember 28, 2024 | markets.businessinsider.comDr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinomaNovember 28, 2024 | businesswire.comDr. Reddy’s and Senores launch Ivermectin tablets USP, 3 mg in U.S.November 26, 2024 | markets.businessinsider.comDr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US MarketNovember 26, 2024 | businesswire.comDr. Reddy’s Gains Strong Rating Amid Robust GrowthNovember 20, 2024 | markets.businessinsider.comDr. Reddy’s Laboratories Reports Record Quarterly GrowthNovember 13, 2024 | markets.businessinsider.comDr. Reddy's Laboratories (NYSE:RDY) Downgraded to Buy Rating by StockNews.comStockNews.com cut Dr. Reddy's Laboratories from a "strong-buy" rating to a "buy" rating in a report on Wednesday.November 13, 2024 | marketbeat.comDr. Reddy’s to Engage with Investors in MumbaiNovember 7, 2024 | markets.businessinsider.comBarclays Lowers Dr. Reddy's Laboratories (NYSE:RDY) Price Target to $17.00Barclays cut their target price on Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating for the company in a research note on Wednesday.November 6, 2024 | marketbeat.comDr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comIndia's Dr Reddy's Q2 profit drops on acquisition cost, impairment chargeNovember 5, 2024 | sg.finance.yahoo.comDr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17%November 5, 2024 | benzinga.comDr. Reddy's Laboratories Limited 2025 Q2 - Results - Earnings Call PresentationNovember 5, 2024 | seekingalpha.comDr. Reddy's Q2 & H1FY25 Financial ResultsNovember 5, 2024 | businesswire.comIndia's Dr Reddy's misses Q2 profit view on weak US demandNovember 5, 2024 | uk.finance.yahoo.comDr. Reddy's Laboratories rises Tuesday, still underperforms marketNovember 5, 2024 | marketwatch.comJourney gets FDA okay for Emrosi, releases preliminary Q3 earnings reportNovember 4, 2024 | msn.comDr. Reddy’s Announces New Employee Stock OptionsNovember 4, 2024 | markets.businessinsider.comJourney Medical announces U.S. FDA approval of EmrosiNovember 4, 2024 | markets.businessinsider.comDr. Reddy's Q2 2025 Earnings PreviewNovember 4, 2024 | msn.comDr Reddy's Laboratories (NYSE:RDY) Stock Quotes, Forecast and News SummaryOctober 29, 2024 | benzinga.comDr. Reddy’s Launches Groundbreaking Drug in IndiaOctober 29, 2024 | markets.businessinsider.comDr. Reddy's Laboratories rises Monday, still underperforms marketOctober 28, 2024 | marketwatch.comJourney Medical announces presentation of DFD-29 dataOctober 26, 2024 | markets.businessinsider.comDr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive YearOctober 25, 2024 | businesswire.comDr. Reddy's Laboratories Stock Set to Split on Tuesday, November 5th (NYSE:RDY)Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) shares are scheduled to split before the market opens on Tuesday, November 5th. The 5-1 split was announced on Thursday, September 12th. The newly created shares will be payable to shareholders after the market closes on Monday, November 4th.October 24, 2024 | marketbeat.comZacks Research Has Optimistic Outlook of RDY Q2 EarningsDr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) - Zacks Research increased their Q2 2027 earnings per share (EPS) estimates for Dr. Reddy's Laboratories in a research note issued to investors on Wednesday, October 16th. Zacks Research analyst R. Department now expects that the company wOctober 18, 2024 | marketbeat.comDr. Reddy's Laboratories outperforms market despite losses on the dayOctober 17, 2024 | marketwatch.comZacks Research Comments on Dr. Reddy's Laboratories Limited's Q2 2026 Earnings (NYSE:RDY)Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) - Equities researchers at Zacks Research boosted their Q2 2026 EPS estimates for shares of Dr. Reddy's Laboratories in a research report issued on Wednesday, October 16th. Zacks Research analyst R. Department now anticipates that the compaOctober 17, 2024 | marketbeat.comDr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness MonthOctober 14, 2024 | businesswire.comArtemis Investment Management LLP Has $4.71 Million Stake in Dr. Reddy's Laboratories Limited (NYSE:RDY)Artemis Investment Management LLP grew its stake in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 280.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 59,306 shares of the coOctober 10, 2024 | marketbeat.comDr. Reddy’s Subsidiary Triumphs in CAR-T Cell Therapy TrialOctober 9, 2024 | finance.yahoo.comAurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple MyelomaOctober 8, 2024 | businesswire.comDr. Reddy’s Unveils New Danish SubsidiaryOctober 8, 2024 | finance.yahoo.comSei Investments Co. Sells 26,041 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)Sei Investments Co. lowered its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 66.8% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,935 shares of the company's stock after selling 26,041 shares during the qOctober 8, 2024 | marketbeat.comHealthcare of Ontario Pension Plan Trust Fund Acquires 283,700 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 318.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 372,900 shOctober 4, 2024 | marketbeat.comCreative Planning Purchases 16,157 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)Creative Planning increased its position in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 22.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 87,522 shares of the company's stock after buying anOctober 3, 2024 | marketbeat.comDr. Reddy’s Acquires Global NRT Leader NicotinellOctober 1, 2024 | finance.yahoo.com Get Dr. Reddy's Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter. Email Address RDY Media Mentions By Week RDY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RDY News Sentiment▼1.160.86▲Average Medical News Sentiment RDY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RDY Articles This Week▼13▲RDY Articles Average Week Get Dr. Reddy's Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News BioNTech News Teva Pharmaceutical Industries News BeiGene News Moderna News Viatris News Genmab A/S News Summit Therapeutics News Sarepta Therapeutics News Catalent News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:RDY) was last updated on 1/5/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAmazon coin set to soar 25X – starting January 20thThis tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RDY Stock Alerts